All In Biotech

Drug Trial Radar · NCT06416410

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

An Open-label, Randomized, Positive Control, Multicenter Phase III Clinical Study. Evaluating JAB-21822 Combined With JAB-3312 Compared Tislelizumab Combined With Pemetrexed + Carboplatin in the First Line for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 392 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

392

Planned (sponsor's estimate)

Start

Aug 7, 2024

Primary completion

Sep 30, 2029

Study completion Aug 2030

Sponsor

Lead sponsor
Allist Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
May 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3 study will evaluate the efficacy of JAB-21822+JAB-3312 versus tislelizumab (PD-1 Ab) combined with pemetrexed+carboplatin as the first line treatment in subjects with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).

Conditions

  • Advanced Non-squamous Non-small-cell Lung Cancer
  • Metastatic Non-squamous Non Small Cell Lung Cancer

Interventions

  • JAB-21822Drug

    JAB-21822 administered orally as a tablet

  • TislelizumabDrug

    Tislelizumab administered as an intravenous (IV) infusion

  • JAB-3312Drug

    JAB-3312 administered orally as a tablet or capsule

  • PemetrexedDrug

    Pemetrexed administered as an intravenous (IV) infusion

  • CarboplatinDrug

    Carboplatin administered as an intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Outcome Progression-free Survival (PFS)Time frame: From Baseline up to 4 years

Locations

37 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Province cancer hospital

    Hefei, Anhui, China · Not yet recruiting

  • Pecking Union Medical College Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Cancer Hospital Chinese Academy Of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Tiantan Hospital, Captal Medical University

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Chest Hospital ,Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • Fujian cancer Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • The first Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China · Not yet recruiting

  • Cancer Hospital Chinese Academy Of medical Sciences Shenzhen Center

    Shenzhen, Guangdong, China · Not yet recruiting

  • Guangxi Medical University Cancer hospital & Guangxi Cancer Institute

    Nanning, Guangxi, China · Not yet recruiting

  • Cangzhou hospital of integrated TCM-WM Hebei

    Cangzhou, Hebei, China · Recruiting

  • Harbin Medical University Cancer Hospital-Mammary gland of internal

    Haerbin, Heilongjiang, China · Not yet recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Not yet recruiting

  • The First Affiliated Hosipital Of Zhengzhou University

    Zhengzhou, Henan, China · Not yet recruiting

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • Tongji Hospital Tongji Medical College of Hust

    Wuhan, Hubei, China · Not yet recruiting

  • Hubei cancer hospital

    Wuhan, Hubei, China · Not yet recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Not yet recruiting

  • Jiangsu province hospital

    Nanjing, Jiangsu, China · Not yet recruiting

  • Wuxi People's Hospital

    Wuxi, Jiangsu, China · Not yet recruiting

  • Jilin cancer hospital

    Jilin City, Jilin, China · Not yet recruiting

  • The First Hospital Of China Medical University

    Shenyang, Liaoning, China · Not yet recruiting

  • Liaoning Cancer Hospital & Institute

    Shenyang, Liaoning, China · Not yet recruiting

  • Shandong Cancer Hospital

    Jinan, Shandong, China · Recruiting

  • LinYi Cancer Hospital

    Linyi, Shandong, China · Not yet recruiting

  • The affiliated hospital of Qingdao university

    Qingdao, Shandong, China · Not yet recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Shanxi province cancer hospital

    Taiyuan, Shanxi, China · Not yet recruiting

  • The First Affiliated Hospital of Xi'An Jiaotong University

    Xi’an, Shanxi, China · Not yet recruiting

  • Sichuan province cancer hospital

    Chengdu, Sichuan, China · Not yet recruiting

  • West China Hospital Sichuan University

    Chengdu, Sichuan, China · Not yet recruiting

  • Tianjin Medical University Cancer Institute Hospital

    Tianjin, Tianjin Municipality, China · Not yet recruiting

  • The First affiliated hospital Zhejiang university school of medicine

    Hangzhou, Zhejiang, China · Not yet recruiting

  • The Second Affiliated Hospital Zhejiang School of Medicine

    Hangzhou, Zhejiang, China · Not yet recruiting

  • Taizhou Hospital Zhejiang Province

    Taizhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.